STOCKS – ACAD, BIIB
MACRO – SPY
MICHAEL KRAMER AND THE CLIENTS OF MOTT CAPITAL OWN ACAD
How ’bout them pollsters… I told you the race would be closer than the polls showed and that Trump had a good chance of winning. I thought he might even win. But I had no idea it would be this tight. I have no idea who will win at this point; I want this whole year to be done with—the market, the pandemic, and now this mess of an election. You’d think in the year 2020, in the most advanced country in the world, we would have better systems to track and count votes. Anyway…”
Stocks jumped as the volality imploded, and the Bluewave sweep (the balance of it) trade melted. The result was a massive shift into the technology sector.
From a technical standpoint, there are a lot of gaps down below that need to be filled. I guess is that after today, and investors have some time to reflect, they may find themselves feeling differently about today’s big gains.
Biogen was the stock of the day, jumping by over 40% ahead of its ADCOM meeting for aducanumab’s potential approval for Alzheimer’s. This stock hasn’t done anything for years. The chart tells you nothing, but you can see how broken up the trading has been.
Acadia reported results after the close with revenue that came in better than expected. I haven’t looked too closely at the results, I saw they missed earnings estimates. This isn’t about the top and bottom-line results for them at this point. What will drive this stock will be a Nuplazid’s potential in Dementia-Related Psychosis and hopefully getting approval from the FDA by the beginning of April.
That’s all for today.
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and, unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.